

Available

Not available

Sites may choose whether or not to participate in domains and interventions offered in the 'moderate' state in either the ICU or ward setting, or both.

Domain A

ANTIBIOTICS

Five alternative antibiotics strategies

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|------------------------------------|------------------|--------------|----------------|
| A.1 - Ceftriaxone + Macrolide | Available | Available | Not available |
| A.2 - Moxifloxacin or levofloxacin | Available | Available | Not available |
| A.3 - Pip-tazo + Macrolide | Available | Available | Not available |
| A.4 - Ceftaroline + Macrolide | Available | Available | Not available |
| A.5 - Amoxiclav + Macrolide | Available | Available | Not available |

MACROLIDE DURATION

Extended macrolide therapy versus short course

Domain M

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|-------------------------------------|------------------|--------------|----------------|
| M.1 - Standard course (3 to 5 days) | Available | Available | Not available |
| M.2 - Extended course (14 days) | Available | Available | Not available |

Domain L

VITAMIN C

Investigating the role of high dose vitamin C

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|---------------------------------|------------------|--------------|----------------|
| C.1 - No vitamin C (no placebo) | Available | Available | Available |
| C.2 - High dose vitamin C iv | Available | Available | Available |

ANTIVIRAL

Three alternative oseltamivir strategies

Domain I

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|---|------------------|--------------|----------------|
| I.1 - No Oseltamivir or other anti-viral agent active against influenza | Available | Available | Not available |
| I.2 - 5 days of Oseltamivir | Available | Available | Not available |
| I.3 - 10 days of Oseltamivir | Available | Available | Not available |

Domain V

VENTILATION

Protocolized versus clinician-preferred strategy

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|-----------------------------|------------------|--------------|----------------|
| V.1 - Clinician preferred | Available | Available | Not available |
| V.2 - Guideline recommended | Available | Available | Not available |

Domain C

**CORTICO-
STEROID**

Three alternative hydrocortisone dosing regimens

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|---|------------------|--------------|----------------|
| C.1 - No Hydrocortisone or other systemic corticosteroid | | | |
| C.2 - IV Hydrocortisone 50 mg every 6 hours for 7 days | | | |
| C.3 - IV Hydrocortisone 50 mg every 6 hours while in septic shock | | | |

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|--|------------------|--------------|----------------|
| Y.1 - No immune modulation for COVID-19 (no placebo) | | | |
| Y.2 - Interferon beta-1a (IFNβ-1a) | | | |
| Y.3 - Anakinra | | | |
| Y.4 - Tocilizumab | | | |
| Y.5 - Sarilumab | | | |

COVID-19 IMMUNE MODULATION

Different immune modulation strategies

Domain Y

Domain X

COVID-19 ANTIVIRAL

Comparison of two different antiviral strategies

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|--|------------------|--------------|----------------|
| X.1 - No antiviral for COVID-19 (no placebo) | | | |
| X.2 - Lopinavir/ritonavir | | | |

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|--|------------------|--------------|----------------|
| H.1 - Standard practice thromboprophylaxis | | | |
| H.2 - Therapeutic anticoagulation | | | |

COVID-19 ANTI-COAGULATION

Different anticoagulation strategies

Domain H

Domain P

COVID-19 IMMUNO-GLOBULIN

No immunoglobulin, convalescent plasma

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|--|------------------|--------------|----------------|
| P.1 - No immunoglobulin against COVID-19 (no placebo) | | | |
| P.2 - CP containing immunoglobulins against SARS-CoV-2 | | | |

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|-----------------------------------|------------------|--------------|----------------|
| S.1 - No simvastatin (no placebo) | | | |
| S.2 - Simvastatin | | | |

COVID-19 STATIN THERAPY
No simvastatin versus simvastatin

Domain
S

| | Non pandemic CAP | COVID Severe | COVID Moderate |
|-----------------------|------------------|--------------|----------------|
| T.1 - No antiplatelet | | | |
| T.2 - Aspirin | | | |
| T.3 - P2Y12 inhibitor | | | |

**Domain
T**

COVID-19 ANTIPLATELET
Three alternative antiplatelet strategies

